验方归芪增血合剂对晚期肺鳞癌化疗相关不良反应的改善效果

Improvement of chemotherapy-induced adverse reactions in advanced lung squamous cell carcinoma with Guiqi Zengxue mistura

目的观察归芪增血合剂对晚期肺鳞癌化疗相关不良反应的改善效果。方法选取2015年7月~2019年2月台州市中心医院收治的晚期肺鳞癌患者88例,其中对照组44例,给予吉西他滨联合顺铂方案进行化疗,观察组44例,在对照组治疗基础上给予归芪增血合剂治疗,观察两组患者治疗后不良反应发生率,并比较化疗前后免疫功能、机体应激反应水平及化疗后生活质量差异及疗效差异。结果观察组患者化疗后白细胞计数下降、粒细胞减少、血红蛋白降低及血小板计数减少等骨髓抑制相关不良反应发生率与对照组比较均有减少,差异有统计学意义(均P<0.05);治疗后两组各免疫指标均有明显改善,差异有统计学意义(均P<0.05);化疗后各应激指标均有明显改善,观察组一氧化氮(NO)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)均低于对照组,差异有统计学意义(均P<0.05);化疗后观察组生理职能、情感职能、躯体疼痛、总体健康、活力以及平均得分等生活质量评分均低于对照组,差异有统计学意义(均P<0.05)。结论晚期肺鳞癌患者行药物化疗过程中给予归芪增血合剂可明显改善由化疗药物导致的骨髓抑制,提高免疫功能,降低机体应激反应水平,改善化疗后生活质量,值得在临床上予以推广实施。

Objective To observe the improvement of chemotherapy-induced adverse reactions(ARs)in advanced lung squamous cell carcinoma with Guiqi Zengxue mistura.Methods Patients with advanced lung squamous cell carcinoma admitted to Taizhou Central Hospital from July 2015 to February 2019 were selected as study subjects.A total of 44 patients in the control group were given chemotherapy with gemcitabine+cisplatin,while 44 patients in the observation group were given Guiqi Zengxue mistura on the basis of treatment in the control group.The incidence of ARs after treatment in both groups was observed.The differences in immune function,level of body stress response before and after chemotherapy,and differences in quality of life(QoL)and efficacy after chemotherapy were compared between the two groups.Results The incidence of myelosuppression-related ARs such as leukocyte decline,granulocytopenia,hemoglobin reduction and thrombocytopenia in the observation group after chemotherapy was lower than that in the control group,with statistically significant differences(all P<0.05).All immune indicators in both groups improved significantly after treatment,with statistically significant differences(all P<0.05).All stress indicators improved significantly after chemotherapy,and the levels of nitric oxide(NO),glutathione peroxidase(GSH-Px)and malondialdehyde(MDA)in the observation group were lower than those in the control group,with statistically significant differences(all P<0.05).The QoL scores of physical function,emotional function,somatic pain,general health,vitality and the mean score were lower in the observation group than those in the control group after chemotherapy,with statistically significant differences(all P<0.05).Conclusion During drug chemotherapy for patients with advanced lung squamous cell carcinoma,the administration of Guiqi Zengxue mistura can significantly improve myelosuppression caused by chemotherapy drugs,enhance immune function,reduce the level of body stress response,and improve post-chemotherapy QoL,which is worthy of promotion and implementation in clinical practice.